Ocugen Shares Face Mounting Pressure as Solvency Concerns Deepen

Quarterly Results Present Mixed Financial Picture

The financial outlook for Ocugen has grown increasingly precarious, with the biotechnology firm’s stock extending losses for five consecutive trading sessions following its quarterly earnings release. This sustained decline occurred despite the company delivering a positive revenue surprise, highlighting investor alarm over a more fundamental threat: the company’s warning about potential insolvency.

Ocugen’s third-quarter 2025 financial performance revealed contradictory signals. While revenue reached $1.75 million, significantly exceeding analyst projections of $0.44 million, the company’s per-share loss of $0.07 surpassed the consensus forecast of $0.06. The net loss widened substantially to $20.05 million, marking a sharp increase from the $12.97 million loss recorded during the same quarter last year.